Related Experiment Video
Updated: Aug 11, 2026
Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
Antimonocyte chemoattractant protein-1 gene therapy attenuates graft vasculopathy
Akio Saiura1, Masataka Sata, Ken-ichi Hiasa
1Department of Surgery, University of Tokyo, Graduate School of Medicine, Japan.
Insights
Gene therapy targeting monocyte chemoattractant protein-1 (MCP-1) significantly reduced intimal hyperplasia in cardiac transplants. This approach may offer a new treatment for graft vascular disease, improving long-term transplant survival.
Area of Science:
- Cardiovascular Research
- Immunology
- Transplantation Biology
Background:
- Accelerated coronary arteriosclerosis, or graft vasculopathy, is a major challenge in cardiac transplant recipients.
- The exact cause of graft vasculopathy is unclear, and effective treatments are lacking.
- Monocyte chemoattractant protein-1 (MCP-1) expression is implicated in transplant arteriosclerosis development.
Purpose of the Study:
- To investigate the efficacy of anti-monocyte chemoattractant protein-1 (MCP-1) gene therapy in preventing intimal hyperplasia.
- To evaluate the role of the MCP-1/chemokine receptor 2 (CCR2) signaling pathway in graft vasculopathy.
Main Methods:
- A mouse model of cardiac transplantation was used.
- Mice received gene transfer of a dominant-negative form of MCP-1 (7ND) or a control vector.
- Cardiac allografts were transplanted, and the development of intimal hyperplasia was assessed.
Main Results:
- 7ND gene transfer significantly reduced mononuclear cell accumulation in graft coronary arteries at 1 week.
- The therapy attenuated lesion development at 8 weeks, showing a lower intima/media ratio.
- A significant reduction in intima/media ratio was observed in the 7ND group compared to controls.
Conclusions:
- The MCP-1/CCR2 signaling pathway is crucial in the pathogenesis of graft vasculopathy.
- Anti-MCP-1 gene therapy demonstrates potential as a novel treatment for graft vascular disease.
- This therapeutic strategy may improve outcomes for cardiac transplant recipients.
Objective:
Accelerated coronary arteriosclerosis remains a major problem in the long-term survival of cardiac transplant recipients. However, the pathogenesis of graft vasculopathy is poorly understood, and there is no effective therapy. Transplant arteriosclerosis is characterized by early mononuclear cell attachment on the transplanted vessel followed by development of concentric neointimal hyperplasia. Early and persistent expression of monocyte chemoattractant protein-1 (MCP-1) in cardiac allografts has been implicated for the pathogenesis of transplant arteriosclerosis.
Methods And Results:
We investigated whether anti-MCP-1 gene therapy can inhibit the development of intima hyperplasia in a mouse model of cardiac transplantation. Either the dominant-negative form of MCP-1 (7ND) or control vector was transfected into the skeletal muscles of B10.D2 mice. Cardiac allografts from DBA/2 mice were transplanted heterotopically into B10.D2 mice. 7ND gene transfer was associated with a significant reduction of the number of mononuclear cells accumulating in the lumen of the graft coronary arteries at 1 week and an attenuation of the development of the lesion at 8 weeks (intima/media ratio 0.79+/-0.05 versus 0.48+/-0.04).
Conclusions:
The MCP-1/chemokine receptor 2 (CCR2) signaling pathway plays a critical role in the pathogenesis of graft vasculopathy. This new anti-MCP-1 gene therapy might be useful to treat graft vascular disease.
More Related Videos
11:13Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
Published on: April 7, 2016
09:46Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
Published on: February 26, 2021
